Ogeda is a clinical-stage drug discovery company dedicated to creating new medicines for unmet medical needs.
Ogeda’s lead product, fezolinetant (ESN364), has shown positive results in a Phase IIa study in the treatment of menopausal hot flashes and further clinical studies are in PolyCystic Ovary Syndrome (PCOS) and Uterine Fibroids are in progress. In addition, Ogeda has a pipeline of products advancing toward clinical development in the fields of endocrine, inflammation and CNS diseases.
Our pipeline contains both clinical as well as early pre-clinical programs in different therapeutic areas. All programs have a GPCRs- and small-molecule focus.